Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

BACKGROUND: A 12-dose, once-weekly regimen of isoniazid and rifapentine (3HP) is effective in preventing tuberculosis (TB) among people living with HIV (PLHIV). We sought to identify potential barriers to and facilitators of acceptance and completion of 3HP treatment from the perspective of people l...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Implement Sci Commun
Glavni autori: Semitala, Fred C., Musinguzi, Allan, Ssemata, Jackie, Welishe, Fred, Nabunje, Juliet, Kadota, Jillian L., Berger, Christopher A., Katamba, Achilles, Kiwanuka, Noah, Kamya, Moses R., Dowdy, David, Cattamanchi, Adithya, Katahoire, Anne R.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247167/
https://ncbi.nlm.nih.gov/pubmed/34193311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s43058-021-00173-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items